Yumi Watanabe
5PUBLICATIONS
1CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 14, 2025
Factors Predicting the Efficacy of Valbenazine and Exacerbation of Tardive Dyskinesia After Valbenazine Discontinuation in Japanese Patients: A Post Hoc Analysis of the J-KINECT Study.Yumi Watanabe, Yutaka Susuta, Hideaki Masui
|Aug 26, 2024
Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study.Yumi Watanabe, Yutaka Susuta, Mieko Nagano
|Sep 17, 2022
Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).Jun Horiguchi, Koichiro Watanabe, Kazuoki Kondo
|Feb 24, 2018
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.Shin-Ichi Harashima, Nobuya Inagaki, Kazuoki Kondo
|Aug 09, 2017
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo
Pageof 1
